In general, new and more selective HDAC6 inhibitors have been disclosed as useful tools to counteract tumor progression [17,18], although it was also reported that the selective inhibition of HDAC6 is not necessarily related to an anticancer activity, as observed for Tubathian A (Figure 3) and related compounds [19]. This evidence concerns the gene HDAC6 and neoplasm.